Eligibility for alirocumab or evolocumab treatment in 1090 hypercholesterolemic patients referred to a regional cholesterol treatment center with LDL cholesterol ≥70 mg/dL despite maximal-tolerated LDL-cholesterol-lowering therapy

BACKGROUND: Proprotein convertase subtilisin/kexin type 9 inhibitors, Praluent (alirocumab [ALI]) and Repatha (evolocumab [EVO]) have been approved as adjuncts to the standard-of-care maximal-tolerated dose (MTD) of low-density lipoprotein cholesterol (LDLC)-lowering therapy (LLT), statin therapy, i...

Descripción completa

Detalles Bibliográficos
Autores principales: Jetty, Vybhav, Glueck, Charles J, Lee, Kevin, Goldenberg, Naila, Prince, Marloe, Kumar, Ashwin, Goldenberg, Michael, Anand, Ishan, Wang, Ping
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2017
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5505680/
https://www.ncbi.nlm.nih.gov/pubmed/28740397
http://dx.doi.org/10.2147/VHRM.S133690

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5505680/
https://www.ncbi.nlm.nih.gov/pubmed/28740397
http://dx.doi.org/10.2147/VHRM.S133690

Ejemplares similares